Receptor, erbB-2 - Genetics
Research News and Information

Tuesday, November 24, 2009

Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.

13 Oct 2009 Hepatitis B x antigen, or HBxAg, contributes importantly to the pathogenesis of hepatocellular carcinoma (HCC). Given that HBxAg constitutively activates beta-catenin and that upregulated ErbB-2 promotes beta-catenin signaling in other tumor types, ... Read more...

HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens.

29 Sep 2009 Published studies have reported widely variable incidence of HER2/neu (c-erbB-2) protein expression and HER2/neu (c-erbB-2) gene amplification in cervical carcinoma. We examined tissue microarrays (TMAs) constructed from 814 formaldehyde-fixed ... Read more...

Emerging technologies for assessing HER2 amplification.

29 Sep 2009 Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated for determining the HER2 ... Read more...

Latest indexed articles for 'Receptor, erbB-2 - Genetics'

These are the very latest articles for this heading:

• Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. 13 Oct 2009
• HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 29 Sep 2009
• Emerging technologies for assessing HER2 amplification. 29 Sep 2009
• Gene expression of circulating tumour cells in breast cancer patients. 26 Sep 2009
• Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. 19 Sep 2009
• The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. 16 Sep 2009
• Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. 13 Sep 2009
• Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. 6 Sep 2009
• Cancer: The fat and the furious. Sep 2009
• Personalizing therapy for metastatic breast cancer. 30 Aug 2009
• Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. 30 Aug 2009
• Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. 30 Aug 2009
• Tyrosine-phosphorylation of the 12th armadillo-repeat of beta-catenin is associated with cadherin dysfunction in human cancer. 30 Aug 2009
• Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. 29 Aug 2009
• Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. 25 Aug 2009
• Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. 17 Aug 2009
• Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. 16 Aug 2009
• Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. 8 Aug 2009
• HER-2/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest. 30 Jul 2009
• Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Receptor, erbB-2'

Definition: A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.

Registry Number: EC 2.7.1.112

Descriptor UI: D018719

Alternative terms: Receptor, erbB-2; Receptor, erbB 2; erbB-2 Receptor; neu Receptor; Proto-Oncogene Protein p185(neu); Proto-Oncogene Proteins c-erbB-2; Proto Oncogene Proteins c erbB 2; p185(c-neu); Receptors, erbB-2; Receptors, erbB 2; erbB-2 Receptors; erbB-2 Proto-Oncogene Protein; Proto-Oncogene Protein, erbB-2; erbB 2 Proto Oncogene Protein; erbB-2 Receptor Protein-Tyrosine Kinase; erbB 2 Receptor Protein Tyrosine Kinase; neu Proto-Oncogene Protein; Proto-Oncogene Protein, neu; neu Proto Oncogene Protein; HER-2 Proto-Oncogene Protein; HER 2 Proto Oncogene Protein; Proto-Oncogene Protein, HER-2; Proto-Oncogene Protein HER-2; Proto Oncogene Protein HER 2; Receptor, neu; Oncogene Protein HER-2; Oncogene Protein HER 2; c-erbB-2 Protein; c erbB 2 Protein;

Related Mesh Headings: Genes, erbB-2;

Allowable Qualifiers: administration & dosage; analysis; antagonists & inhibitors; biosynthesis; blood; classification; deficiency; drug effects; genetics; history; immunology; isolation & purification; metabolism; physiology; radiation effects; therapeutic use; ultrastructure; chemistry; agonists;

Tree Number: D08.811.913.696.620.682.725.400.150; D12.776.543.750.060.374; D12.776.543.750.750.400.350; D12.776.624.664.700.642; D23.101.840.642;

History Note: 2000(1995); use RECEPTOR, ERBB-2 (NM) 1985-1994